---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Glucocorticoids and recombinant growth hormone"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Glucocorticoids and recombinant growth hormone. Topics: Glucocorticoids for refractory hypoglycemia in insulinoma: ENETS 2023 guidance, Glucocorticoids in insulinoma: dose and adverse effects, Glucocorticoids and recombinant growth hormone in NICTH: clinical review, Glucocorticoid dose threshold and reversibility in NICTH: case series, and 4 further topics. 8 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/glucocorticoids-and-recombinant-growth-hormone"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Glucocorticoids and recombinant growth hormone

<a id="heading-2.2.2.1.10"></a>

## 2.2.2.1.10 Glucocorticoids and Recombinant Growth Hormone

<a id="topic-2.2.2.1.10-1"></a>

### Glucocorticoids for refractory hypoglycemia in insulinoma: ENETS 2023 guidance

> “First-line medical therapy for advanced insulinoma consists of diazoxide (50–600 mg daily).”
> “In cases of refractory hypoglycaemia, incidental descriptions also support the use of glucocorticoids, verapamil, and diphenylhydantoin [5, D].”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.10-2"></a>

### Glucocorticoids in insulinoma: dose and adverse effects

> “Glucocorticoids are sometimes used to control the hypoglycemia but their chronic use poses a significant risk for side effects (eg, weight gain, neuropsychiatric disturbances, hypertension, secondary [opportunistic] infections).”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Glucocorticoids inhibit insulin release and increase peripheral insulin resistance and have been used in the management of refractory hypoglycaemia at a low dose (prednisolone 2.5 mg daily, dexamethasone 0.5−4 mg) where other agents have been ineffective”

Source: [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)

<a id="topic-2.2.2.1.10-3"></a>

### Glucocorticoids and recombinant growth hormone in NICTH: clinical review

> “In such cases, we suggest consideration of local antitumor therapies for disease control and trial of glucocorticoids alone or in combination with GH.”
> “Diazoxide and octreotide have no role in NICTH.”
> “Glucocorticoids (including dexamethasone, hydrocortisone, prednisolone, and prednisone, typically in doses equivalent to prednisone 30–60 mg/d) are the most extensively described medical therapy for NICTH”
> “Recombinant human GH (rhGH) at supraphysiological doses of 3–12 mg daily has been successful in many cases”
> “Additionally, we propose that cost could be a limiting factor, especially for long-term therapy.”
> “Combination therapy was successful (including freedom from iv glucose or dextrose) in multiple cases where monotherapy with either failed”
> “Although there are no randomized controlled trials to guide therapy, ample case reports and series are available in the literature over the past quarter century.”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.2.1.10-4"></a>

### Glucocorticoid dose threshold and reversibility in NICTH: case series

> “Therapeutic treatment with glucocorticoids confirmed previous studies showing the suppressive effect on tumour (big) IGF-II production.”
> “The present data show that the effect was dose-dependent and reversible if doses were below a critical level.”
> “This effectiveness was only achieved when the dose exceeded a threshold level specific to the patient.”

Source: [Teale and Wark (2004)](https://pubmed.ncbi.nlm.nih.gov/15049960/)

<a id="topic-2.2.2.1.10-5"></a>

### Glucocorticoids compared with growth hormone in NICTH: effect on big IGF-II

> “Two groups each of 4 patients, all diagnosed as cases of NICTH, were treated with either hGH or glucocorticoids.”
> “Glucocorticoid therapy has been demonstrated to consistently reverse the biochemical abnormalities caused by tumour-derived big IGF-II compared with the potentially adverse stimulatory effects of hGH treatment in causing increases in serum levels of big IGF-II.”

Source: [Teale and Marks (1998)](https://pubmed.ncbi.nlm.nih.gov/9876347/)

<a id="topic-2.2.2.1.10-6"></a>

### Glucocorticoid minimum effective doses and growth hormone combination in IGF-2-mediated hypoglycemia

> “The minimum effective dose in one review of NICTH with solitary fibrous tumours was 25 mg/day for prednisolone, 32 mg/day for methylprednisolone, and 2 mg/day for dexamethasone”
> “Recurrent hypoglycemia is also seen when the glucocorticoid dose is reduced below the aforementioned thresholds, limiting their long-term utility”
> “The combination of rGH with glucocorticoids at low doses, as in case 2, is an effective regimen with minimal adverse effects in patients with inoperable tumours”
> “When the tumour is unresectable, moderate-dose glucocorticoids, low-dose glucocorticoids in combination with recombinant growth hormone, and pasireotide are medical therapies with promising results in controlling NICTH.”

Source: [Vu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10959053/)

<a id="topic-2.2.2.1.10-7"></a>

### Frequency of glucocorticoid use in IGF-2-mediated hypoglycemia: systematic review of 233 patients

> “Medication therapy with corticosteroids, octreotide and diazoxide was used in 91 (39.1%), 18 (7.7%) and 16 (6.9%) cases, respectively.”
> “Management such as octreotide, corticosteroids, diazoxide, embolization, radiotherapy and surgical resection have disparate success rates.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.2.1.10-8"></a>

### Manufacturer statements on medical therapy in NICTH

> “Dextrose, oral glucocorticoids, and glucagon (diazoxide and somatostatin analogs are not effective treatments for hypo from IGF-2 tumors)”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

Additional sources: [Cryer et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19088155/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
